← 返回

小细胞肺癌(SCLC)分子亚型的临床特征与患者结局

英文原题:Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).

查看英文原题

Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).

PubMed 2022/02/27(内容时间) World J Surg Oncol Q1 · IF 2.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们基于 IHC 的研究利用关键转录调控因子的表达模式,验证了所提出的 SCLC 分类。

中文摘要

近期研究显示,根据achaete-scute同源物1(ASCL1)、神经元分化因子1(NEUROD1)和POU结构域2类同源框3(POU2F3)的表达水平,小细胞肺癌(SCLC)可分为四种亚型:SCLC-A(ASCL1主导)、SCLC-N(NEUROD1主导)、SCLC-P(POU2F3主导)和SCLC-I(三阴性或炎症型SCLC)。但关于这些分子亚型临床特征和预后的数据有限。

采用免疫组化(IHC)检测53例可切除SCLC患者样本中的ASCL1、NEUROD1和POU2F3表达。根据这些转录因子的差异表达,或三者均低表达并具有炎症基因特征,将肿瘤分别定义为SCLC-A、SCLC-N、SCLC-P或SCLC-I。分析四种SCLC亚型的临床病理特征、免疫学特征[PD-L1表达和CD8阳性TIL(肿瘤浸润淋巴细胞)密度]及患者结局。

IHC检测显示,53份SCLC样本中ASCL1、NEUROD1和POU2F3阳性者分别为43例(79.2%)、27例(51.0%)和17例(32.1%)。根据IHC结果,SCLC可分为四种亚型:SCLC-A占39.6%、SCLC-N占28.3%、SCLC-P占17.0%、SCLC-I占15.1%。四种亚型的5年总生存率分别为61.9%、69.3%、41.7%和85.7%(P=0.251)。不同SCLC亚型的吸烟状态存在显著差异(P=0.031),但未证实亚型与其他临床病理因素或免疫特征相关。Cox多变量分析显示,N分期(P=0.025)、CD8阳性TIL(P=0.024)、Ki-67水平(P=0.040)和SCLC-P亚型(P=0.023)是可切除SCLC的独立预后因素。

本IHC研究验证了依据关键转录调控因子表达模式划分SCLC亚型的分类方法。SCLC-P与吸烟者相关,并是局限期SCLC的不良预后因素之一。此外,未发现PD-L1表达或CD8阳性TIL密度与SCLC亚型相关。

展开英文摘要原文

Recent studies have shown that according to the expression levels of achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), and POU class 2 homeobox 3 (POU2F3), small cell lung cancer (SCLC) can be divided into four subtypes: SCLC-A (ASCL1-dominant), SCLC-N (NEUROD1-dominant), SCLC-P (POU2F3-dominant), and SCLC-I (triple negative or SCLC-inflamed). However, there are limited data on the clinical characteristics and prognosis of molecular subtypes of SCLC.

Immunohistochemistry (IHC) was used to detect the expression levels of ASCL1, NEUROD1, and POU2F3 in 53 patient samples of resectable SCLC. The subtype was defined by the differential expression of the transcription factors for ASCL1, NEUROD1, and POU2F3 or the low expression of all three factors with an inflamed gene signature (SCLC-A, SCLC-N, SCLC-P, and SCLC-I, respectively). The clinicopathological characteristics, immunological features (programmed death ligand 1 [PD-L1] expression and CD8+ tumor infiltrating lymphocyte [TIL] density), and patient outcomes of the four subtypes of SCLC were analyzed.

Positive ASCL1, NEUROD1, and POU2F3 staining was detected in 43 (79.2%), 27 (51.0%), and 17 (32.1%) SCLC specimens by IHC. According to the results of IHC analysis, SCLC was divided into four subtypes: SCLC-A (39.6%), SCLC-N (28.3%), SCLC-P (17.0%), and SCLC-I (15.1%). The 5-year overall survival (OS) rates of these four subtypes were 61.9%, 69.3%, 41.7%, and 85.7%, respectively (P=0.251). There were significant differences in smoking status among different subtypes of SCLC (P= 0.031). However, we did not confirm the correlation between subtypes of SCLC and other clinicopathological factors or immune profiles. Cox multivariate analysis showed that N stage (P=0.025), CD8+ TILs (P=0.024), Ki-67 level (P=0.040), and SCLC-P (P=0.023) were independent prognostic factors for resectable SCLC.

Our IHC-based study validated the proposed classification of SCLC using the expression patterns of key transcriptional regulatory factors. We found that SCLC-P was associated with smokers and was one of the poor prognostic factors of limited-stage SCLC. In addition, no correlation was found between PD-L1 expression or CD8+ TIL density and SCLC subtypes.

论文信息

作者
Ding XL、Su YG、Yu L、Bai ZL、Bai XH、Chen XZ、Yang X、Zhao R
第一作者单位
Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, China.China
通讯作者单位
Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, China. fdwyy1981@hotmail.com.China
期刊
World journal of surgical oncology2022 Feb 27
原文标识
PubMed 35220975 · DOI 10.1186/s12957-022-02528-y